Navigation Links
Repros' Androxal Shows Highly Statistically Significant Positive,Effects in Men with Secondary Hypogonadism

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jun 5, 2007 - Repros Therapeutics Inc. (NasdaqGM:RPRX) announced topline results of a six month U.S. Phase 3 study of Androxal(TM), an oral drug being developed to restore normal testicular function in men with secondary hypogonadism. Further, Androxal demonstrates non-inferiority in all the endpoints of the study, compared to Androgel(R), a cream which is the leading treatment for low testosterone.

Study Details and Results

This six month, double-blind study compared two doses of oral Androxal, 12.5mg and 25mg, to matching placebo capsules and open label Androgel at any dose to be used per manufacturer's instructions. The study's primary efficacy endpoint was the proportion of patients at month three who showed morning total serum testosterone concentrations within the normal physiological range (300 to 1040 ng/dl). This endpoint was also extended to include the outcome at month six as well as the assessment of non-inferiority to Androgel.

Of the 191 patients enrolled in the trial, 144 patients completed the study. There were 8 and 15 premature drop outs in the 12.5mg and 25mg Androxal arms, respectively, 15 drop outs in the placebo arm, and 13 drop outs in the Androgel arm. There were no drop outs due to an adverse event or lack of compliance in the Androxal treatment groups. The majority of the other drop outs were due to either withdrawal of consent or "lost to follow-up". There were 188 patients in the modified intent-to-treat group ("MITT") consisting of all randomized patients with at least one efficacy evaluation.

The proportion of men in the 12.5mg and 25mg treatment arms with total testosterone in the physiological range at month three using the last observation carried forward was 72.7% and 79.2%, respectively, and those on Androgel and placebo the proportion was 57.4% and 28.3%, respectively. These results confirm non-inferiority to Androge
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Peer Reviewed Journal Article Indicates Repros Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer
2. Repros Proellex Shows Statistically Significant Improvement in Primary Endpoint in Phase 2 Trial in the Treatment of Uterine Fibroids
3. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
4. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
5. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
6. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
7. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
8. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
9. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
10. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
11. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
Post Your Comments:
(Date:5/4/2015)... May 4, 2015 RadiologyAuction will have their first ... and product demonstrations at the end of the auction ... as Kodak and Fuji Cr,s, Agfa and Sony, printers ... first event. Various imaging equipment will be available at ... After years of buying and selling imaging equipment, ...
(Date:5/4/2015)... 2015 Rogne Bioscience, a privately-held biotechnology company ... preclinical and mechanism of action data will be presented ... Dermatology (SID) Annual Meeting being held May 6-9, 2015 ... . Logo - http://photos.prnewswire.com/prnh/20150501/213318LOGO ... a novel, low MW (<1700 daltons) peptide as a ...
(Date:5/4/2015)... -- Bayer HealthCare (Bayer) has entered into an exclusive ... ) on ISIS-FXI Rx, an antisense investigational drug ... the agreement Bayer will further develop and commercialize ISIS-FXI ... As part of the clinical development program, Bayer plans ... in an appropriate patient community. "Bayer is ...
Breaking Medicine Technology:RadiologyAuction Announces Event Starting On May 5th 2Rogne Bioscience to Present Data from Topical Biologic Psoriasis Program at Upcoming SID Annual Meeting 2015 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3
... SINGAPORE , UPPSALA, Sweden and CANTON, Mass. , ... that the US Food and Drug Administration (FDA) has given the ... Mesh, for use in reinforcement of soft tissues where weakness exists. ... synthetic matrix, knitted from two different resorbable fibers that degrade at ...
... SAN FRANCISCO, Calif. , Feb. 5 Poniard Pharmaceuticals, Inc. ... today announced that Ronald Martell , chief executive officer, will provide ... on Tuesday, February 9, 2010 at 1:00 p.m. Eastern ... . , A live audio webcast of the corporate overview will be ...
Cached Medicine Technology:Novus Scientific Receives FDA Clearance for TIGR(TM) Matrix Surgical Mesh - World's 1st Long-Term Resorbable Synthetic Mesh 2Novus Scientific Receives FDA Clearance for TIGR(TM) Matrix Surgical Mesh - World's 1st Long-Term Resorbable Synthetic Mesh 3Poniard Pharmaceuticals to Present at 12th Annual BIO CEO and Investor Conference 2
(Date:5/4/2015)... 05, 2015 The National ... Irene Taylor , Volunteer Executive Director of National ... inductee into its VIP Woman of the Year ... for leadership in business. NAPW is the nation's ... more than 700,000 members and over 200 Local ...
(Date:5/4/2015)... The National Association of Professional Women ... a 2015-2016 inductee into the NAPW VIP Woman of ... distinction for leadership in healthcare. NAPW is the nation's ... than 700,000 members and over 200 operating Local Chapters. ... group of professional women,” says NAPW President Star Jones. ...
(Date:5/4/2015)... (PRWEB) May 05, 2015 The ... Shirley Weis as a 2015-2016 inductee into its ... with this prestigious distinction for leadership in healthcare. NAPW ... women, boasting more than 700,000 members and over 200 ... with this important honor,” says NAPW President Star Jones. ...
(Date:5/4/2015)... IOWA (PRWEB) May 04, 2015 The ... appointed Gregs G. Thomopulos, P.E., Chairman of Stanley ... (ISI) board of directors for a three-year term. ... Association (APWA) and the American Society of Civil Engineers ... a sustainability rating system for civil infrastructure called Envision. ...
(Date:5/4/2015)... 04, 2015 HHT is a rare ... While it can have seemingly mild symptoms like ... events. Hereditary Hemorrhagic Telangiectasia (HHT) is a hereditary ... lack normal capillary connections between an artery and a ... severe nosebleeds, but may also be present in the ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Inducts Irene Taylor into its 2015-2016 VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Jennifer Yates Doherty, Owner of Palmetto Rehabilitation Services, LLC, into its 2015 VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Shirley Weis, President at Weis Associates, LLC, into its 2015-2016 VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Shirley Weis, President at Weis Associates, LLC, into its 2015-2016 VIP Woman of the Year Circle 3Health News:Thomopulos Appointed to Institute for Sustainable Infrastructure Board 2Health News:Frequent Nosebleeds Can Be a Sign of a Rare Undiagnosed Disease - Cure HHT 2Health News:Frequent Nosebleeds Can Be a Sign of a Rare Undiagnosed Disease - Cure HHT 3
... May 20 (ZealousPR) Award-winning Vanity,Fair writer and hospice ... tri-weekly "advice column on dying well,", http://www.TheCheckoutLine.org -- ... who care about them, today. Every Monday, Wednesday and,Friday, ... questions,and offering advice for anyone needing help on the ...
... of developing asthma and allergy because of different conditions ... from the Isle of Wight in the United Kingdom, ... 2008 International Conference in Toronto on Wednesday, May 21., ... asthma and allergy in first-born children is the result ...
... Allows Patients the Ability to Share their Prescription ... Longs Drug,Stores Corporation (NYSE: LDG ) announced ... a platform for sharing of information between,patients and ... of the first,pharmacies to provide their customers with ...
... CHICAGO (May 19, 2008) New research published in ... long-term survival and liver rejection rates are equivalent for ... other races. The study also suggests that although other ... influence long-term survival, race does not. , ...
... ... Leadership, CHICAGO, May 19 Ventas, Inc. (NYSE: VTR ... declared,a regular quarterly dividend of $0.5125 per share, payable in cash ... The dividend is the,second quarterly installment of the Company,s 2008 annual ...
... procedure performed by Dr. Robert S. Bray, Jr. of ... D.I.S.C. Spine ... Roach is living,her dream after successfully qualifying for the 2008 ... one of the country,s preeminent,neurological spinal surgeons specializing in micro ...
Cached Medicine News:Health News:Award Winning Vanity Fair Contributing Editor Judy Bachrach Launches 'TheCheckoutLine.org - An Advice Column on Dying Well' 2Health News:First-born babies' higher asthma and allergy rates due to pregnancy conditions 2Health News:Longs Drugs Partners With Google on the Launch of Google Health 2Health News:Study concludes no racial disparities in long-term outcomes in recipients of liver transplants 2Health News:Ventas Declares Regular Quarterly Dividend of $0.5125 Per Share 2Health News:Ventas Declares Regular Quarterly Dividend of $0.5125 Per Share 3Health News:Ventas Declares Regular Quarterly Dividend of $0.5125 Per Share 4Health News:Ventas Declares Regular Quarterly Dividend of $0.5125 Per Share 5Health News:Successful Back Surgery Propels Olympic Weightlifting Hopeful Melanie Roach to Realize Her Dreams Of Participating in the 2008 Beijing Olympics 2
Universal Hub with Varying Blade Edge Diameters For Mounting the Blade to the Handle; Stainless Steel....
2 Sided Pivoted Closed Ring Design,Pointed And Smooth Sides; in stainless steel....
Blunt Tapered Tip in stainless steel....
... meet the high-quality and ... practices. The optional Profile ... accessory features a unique ... increases the accuracy of ...
Medicine Products: